<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More


Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More


Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More


Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More


Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More


Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More


Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More


Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More


Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More


Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More


Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

How Gut Bacteria Influence Cancer Treatment Efficacy


gut bacteria, microbiota can influence cancer treatment and immunotherapy efficacy and response, including checkpoint inhibitorsOver the past few years, scientists have come to a deeper understanding of how microorganisms can be seen as a major determinant of health and disease, including cancer.

The human body contains around 30 to 50 trillion bacteria, the microbiota, populating complex ecosystems called microbiomes in the skin, nose, mouth, stomach, and intestines. Some 99% of the microbiota in the human body reside in the gastrointestinal microbiome.

Gut Microbiota Shape Immune Response

Up to now, most oncology therapies have focused on killing cancer cells, through a variety of different approaches. However, increasing evidence has been documented that gut microbiota has an important impact in shaping systemic immune response.

A growing number of studies have revealed how gut microbiota change immune response and influence the efficacy of anticancer immunotherapeutics, e.g. anti-CTLA-4 and anti-PD-L1 antibody treatment, both in preclinical and clinical settings.

Response to Anti-PD-1 is Microbiome Modulated in Melanoma Patients

One recent clinical study reported that the composition of patient gut microbes appears to be a determining factor for immunotherapy response using an anti-PD-1 antibody in melanoma patients. Among the 93 patients treated with the anti-PD-1 immune checkpoint blockade, the researchers studied gut microbiome samples from 30 responders and 13 non-responders.

They found:

  • A greater diversity of types of bacteria in the responders’ microbiomes.
  • Increased abundance in responders of the Ruminococcaceae family of bacteria within the Clostridiales order.
  • Increased abundance of Bacteriodales in non-responders and a much lower diversity of bacteria.

They also founded that responders had significantly increased immune infiltrates in their tumors, including the presence of CD8+ killer T cells, correlated to the abundance of a specific bacterium.

Utilizing the Microbiome as a Predictive Biomarker or Potential Cancer Treatment

These findings shed light on using the gut microbiome either as a biomarker to differentiate responders from non-responders in cancer immunotherapy, or as a potential alternative to cancer therapeutics.

In addition, with increased interest in how to transform non-responsive tumors to responsive tumors, future studies will explore combinations of immunotherapy and fecal transplantation as well as other strategies that may involve the use of antibiotics to selectively deplete certain bacteria or pre- or probiotic supplements to enhance certain bacteria into the gut.

Cancer Treatments can have a Negative Effect on Microbiota

Alternatively, chemotherapy and radiotherapy have detrimental effects on the gut-microbiota, leading to dysbiosis. Dysbiosis refers to a negatively altered microbiota, where symbiosis is affected. Immunotherapies also come with side effects, some of which lead to the development of colitis. Fecal transplant has been shown to be effective in treating inflammatory bowel disease and colitis.

Currently, in addition to augmenting immunotherapy efficacy, strategies are being aimed at restoring a balanced gut-microbiota via microbiota transplantation in order to mitigate side effects related to immunotherapy.

Profile the Microbiome to Potentiate Immunotherapy Response

To sum up, gut microbes could influence cancer outcomes through their interaction with host immunity. Profiling the individual’s gut microbiome needs to be further evaluated as a tool to potentiate immunotherapy response.

Further reading on the topic:

Zitvogel et al. Cancer and the gut microbiota: An unexpected link. Sci Transl Med. 2015; 7(271).

Roy and Trinchieri. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017; 17(5): 271-285.

Bhatt et al. The role of the microbiome in cancer development and therapy. CA Cancer J Clin 2017; 67(4): 326-344.

Related Posts